Tibet Aim Pharm

Tibet Aim Pharm FCF Margin

The Free Cash Flow Margin of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 18.11 %. In the previous year, Free Cash Flow Margin was 15.24 % — a change of 18.85% (higher).

FCF Margin

18.11 %

YoY

18.85%

Last updated:

Free Cash Flow Margin of Tibet Aim Pharm is 2025 18.11 % . Free Cash Flow Margin of Tibet Aim Pharm was 2024 15.24 % . It decreases by 18.85% higher compared to the previous year.

The Tibet Aim Pharm FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-11.13 CNY
Jan 1, 2019
-20.11 CNY
Jan 1, 2020
10.51 CNY
Jan 1, 2021
11.62 CNY
Jan 1, 2022
7.62 CNY
Jan 1, 2023
24.54 CNY
Jan 1, 2024
15.24 CNY
Jan 1, 2025
18.11 CNY
The Tibet Aim Pharm FCF Margin history
YEARFCF MarginYoY
18.11 %+18.85%
15.24 %-37.91%
24.54 %+222.20%
7.62 %-34.47%
11.62 %+10.65%
10.51 %-152.24%
-20.11 %+80.66%
-11.13 %-1,683.90%
0.70 %-91.78%
8.55 %-140.19%
-21.29 %+44.13%
-14.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

Free Cash Flow Margin of Tibet Aim Pharm is 18.11 % in 2025.

Free Cash Flow Margin of Tibet Aim Pharm changed from 15.24 % to 18.11 %, representing a 18.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Tibet Aim Pharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm